etylmetylhydroksypyrydyna | Mexicor capsules 100 mg, 20 pcs.

Latin name

Mexicor

Release form

Hard gelatin capsules, size No. 2, yellow capsule content - granules, consisting of granules and powder, white or white with a yellowish tint.



packaging 10 pcs - blister packs (2) - packs of cardboard.

Indications

CHD (as part of complex therapy)

ischemic stroke (as part of combination therapy)

discirculatory encephalopathy

mild to moderate cognitive impairment

Contraindications

acute liver dysfunction

acute renal dysfunction

children and adolescents under 18 years of age (efficacy and safety not established)

pregnancy

lactation (breast-feeding)

hypersensitivity to the drug.

Use during pregnancy and lactation

The use of the drug during pregnancy and lactation is contraindicated.

Composition

1 caps.

ethylmethylhydroxypyridine succinate 100 mg

Excipients: potato starch - 54.5 mg, povidone (low molecular weight polyvinylpyrrolidone medical 12600 ± 2700) - 4 mg, lactose (milk sugar) - 40 mg, magnesium stearate - 0.5 mg, microcrystalline cellulose - 1 mg.

Composition of hard gelatin capsule No. 2: gelatin - 59.3189 mg, titanium dioxide (E171) - 1.22 mg, sunset sunset dye yellow (E110) - 0.0036 mg, quinoline yellow dye (E104) - 0.4575 mg.

Dosage and administration

mexicor® is prescribed orally.

The initial dose is 100 mg (1 caps.) 3 times / day. Next, the dose should be gradually increased, depending on the clinical course of the disease and the tolerability of the therapy.

The maximum daily dose should not exceed 800 mg, a single - 200 mg. It is desirable to distribute the daily dose of the drug into several doses throughout the day. The course of treatment with Mexico ends gradually, reducing the daily dose of the drug by 100 mg.

The duration of the course of therapy with Mexico when used as part of the complex treatment of coronary heart disease and circulatory disorders of the brain should be at least 1. 5-2 months Repeated courses (on the recommendation of a doctor), it is advisable to conduct in the spring-autumn periods.

With the complex therapy of discirculatory encephalopathy, lungs and moderate cognitive impairment, Mexico® is prescribed without limitation of the course of treatment for the duration, at a dose of 100 mg 3-4 times / day.

Side effects of the

From the digestive system: rarely - dyspepsia, dry mouth, nausea, diarrhea that quickly disappear on their own or when the drug is canceled with prolonged use - flatulence.

From the side of the central nervous system: with prolonged use - sleep disturbances (drowsiness or falling asleep).

Other: rarely - allergic reactions.

The drug is usually well tolerated.

Drug interaction

Mexicore® enhances the action of anticonvulsants (carbamazepine), antiparkinsonian agents (levodopa) and benzodiazepine anxiolytics.

Mexicore® increases the anti-anginal activity of nitrates and the antihypertensive activity of ACE inhibitors and beta-blockers.

Mexicore® reduces the toxic effects of ethanol.

Overdose

Symptoms: sleep disorder (insomnia), in some cases drowsiness.

Treatment: the development of symptoms of overdose, as a rule, does not require the use of relief agents, these symptoms of sleep disorders disappear on their own within a day. In particularly severe cases, it is recommended to use one of the sleeping pills and anxiolytic medicines for oral administration (nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg).

Storage conditions

In the dark place at a temperature of no higher than 25 РC.

Keep out of the reach of children.

The Expiration of

is 3 years.

Do not use after the expiry date stated on the package.

Deystvuyuschee substance

Ethylmethylhydroxypyridine succinate



pharmacy terms for

dosage form

dosage form

capsules